P02766 (TTHY_HUMAN) Homo sapiens (Human)

Transthyretin UniProtKBInterProSTRINGInteractive Modelling

147 aa; Sequence (Fasta) ; 1 identical sequence: Homo sapiens: E9KL36

Available Structures

413 Experimental Structures

DescriptionPDB IDOligo-stateRangeSeq id (%)Ligands
The structure of human retinol binding protein with its carrier protein transthyretin reveals inter… Heteromer
P02753;
21-147
99.19RTL;
Complex of TTR and RBP4 and Oleic Acid Heteromer
P02753;
21-144
10011×SO4;OLA;
RETINOL BINDING PROTEIN COMPLEXED WITH TRANSTHYRETIN Heteromer
P02753;
25-147
99.19REA;
Crystal structure of the transthyretin-retinol binding protein-Fab complex Heteromer
P02753;
27-145
100RTL;
Atomic-resolution structure of a cross-beta protofilamenthomo-16-mer125-135
100
Cryo-EM structure of a twisted-dimer transthyretin amyloid fibril from vitreous body of the eyehomo-14-mer31-143
98.91
transthyritin derived amyloid fibril from patient with hereditary V30M ATTR amyloidosishomo-11-mer31-143
98.91
Crystal Structure of TTR-G67Rhomo-8-mer22-146
99.15
Wild type ATTR amyloid fibril from senile systemic amyloidosishomo-7-mer31-143
100.0
ATTRG47E amyloid fibril from hereditary ATTR amloidosishomo-6-mer31-143
100.0
ATTRV20I amyloid fibril from hereditary ATTR amloidosishomo-6-mer31-143
98.91
ATTRV122I amyloid fibril from hereditary ATTR amloidosishomo-6-mer31-143
98.91
Cardiac amyloid fibrils extracted from a wild-type ATTR amyloidosis patienthomo-5-mer31-144
100.0
Cryo-EM structure of cardiac amyloid fibril from a variant ATTR I84S amyloidosis patient-3, wild-ty…homo-5-mer31-144
98.92
Cardiac amyloid fibrils extracted from a wild-type ATTR amyloidosis patienthomo-5-mer31-143
100.0
Cryo-EM structure of wild-type transthyretin amyloid from heart tissuehomo-5-mer31-143
100.0
Cryo-EM structure of cardiac amyloid fibril from a variant ATTR I84S amyloidosis patienthomo-5-mer32-144
98.77
Cryo-EM structure of cardiac amyloid fibril from a wild-type amyloidosis patienthomo-5-mer32-143
100.0
Cryo-EM structure of cardiac amyloid fibril from a variant ATTR P24S amyloidosis patienthomo-5-mer32-143
98.88
Cryo-EM structure of cardiac amyloid fibril from a variant ATTR I84S amyloidosis patienthomo-5-mer32-142
98.8
THE X-RAY CRYSTAL STRUCTURE REFINEMENTS OF NORMAL HUMAN TRANSTHYRETIN AND THE AMYLOIDOGENIC VAL30ME…homo-4-mer21-147
99.21
TERTIARY STRUCTURES OF THREE AMYLOIDOGENIC TRANSTHYRETIN VARIANTS AND IMPLICATIONS FOR AMYLOID FIBR…homo-4-mer21-147
99.21
THE X-RAY CRYSTAL STRUCTURE REFINEMENTS OF NORMAL HUMAN TRANSTHYRETIN AND THE AMYLOIDOGENIC VAL30ME…homo-4-mer21-147
100
THE X-RAY CRYSTAL STRUCTURE REFINEMENTS OF NORMAL HUMAN TRANSTHYRETIN AND THE AMYLOIDOGENIC VAL30ME…homo-4-mer21-147
99.21
TERTIARY STRUCTURES OF THREE AMYLOIDOGENIC TRANSTHYRETIN VARIANTS AND IMPLICATIONS FOR AMYLOID FIBR…homo-4-mer21-147
99.21
TERTIARY STRUCTURES OF THREE AMYLOIDOGENIC TRANSTHYRETIN VARIANTS AND IMPLICATIONS FOR AMYLOID FIBR…homo-4-mer21-147
99.21
TERTIARY STRUCTURES OF THREE AMYLOIDOGENIC TRANSTHYRETIN VARIANTS AND IMPLICATIONS FOR AMYLOID FIBR…homo-4-mer21-147
99.21
TRANSTHYRETIN (DEL VAL122)homo-4-mer21-147
100
TERTIARY STRUCTURES OF THREE AMYLOIDOGENIC TRANSTHYRETIN VARIANTS AND IMPLICATIONS FOR AMYLOID FIBR…homo-4-mer21-147
99.21
STRUCTURAL ASPECTS OF INOTROPIC BIPYRIDINE BINDING: CRYSTAL STRUCTURE DETERMINATION TO 1.9 ANGSTROM…homo-4-mer25-147
99.19MIL;
TRANSTHYRETIN (ALSO CALLED PREALBUMIN) COMPLEX WITH 3',5'-DINITRO-N-ACETYL-L-THYRONINEhomo-4-mer27-147
100P28;
MECHANISM OF MOLECULAR RECOGNITION. STRUCTURAL ASPECTS OF 3,3'-DIIODO-L-THYRONINE BINDING TO HUMAN …homo-4-mer30-147
99.15T33;
TRANSTHYRETIN (ALSO CALLED PREALBUMIN) COMPLEX WITH THYROXINE (T4)homo-4-mer30-147
100SO4;T44;
Human transthyretin (also called prealbumin) complex with 3, 3',5,5'-tetraiodothyroacetic acid (t4a…homo-4-mer28-145
100T4A;
CRYSTAL STRUCTURE DETERMINATION AT 2.3A OF HUMAN TRANSTHYRETIN-3',5'-DIBROMO-2',4,4',6-TETRA-HYDROX…homo-4-mer29-146
99.15FL9;
High Resolution Structure of Wild Type Human Transthyretin in Complex with 3,3',5,5'-tetrachloro-[1…homo-4-mer30-146
100PCQ;
Human transthyretin (TTR) complexed with 16-alpha-bromo-estradiolhomo-4-mer29-145
100ESZ;EDO;
Human transthyretin (TTR) complexed with ferulic acid and curcumin.homo-4-mer29-145
100CUR;NA;EDO;FER;
Human transthyretin (TTR) complexed with curcuminhomo-4-mer29-145
100CUR;NA;EDO;
Human transthyretin (TTR) complexed with 3-(9H-fluoren-9-ylideneaminooxy)ethanoic acidhomo-4-mer29-145
100ES8;EDO;
Dual binding mode for 3-(9H-fluoren-9-ylideneaminooxy)propanoic acid binding to Human transthyretin…homo-4-mer29-145
1007BD;EDO;
Structure of TTR R104H: a non-amyloidogenic variant with protective clinical effectshomo-4-mer29-145
99.14
Crystal Structure of V30M transthyretin complexed with (-)-epigallocatechin gallate (EGCG)homo-4-mer29-145
99.14KDH;GOL;
Neutron structure of human transthyretin (TTR) at room temperature to 2.0A resolution (Laue)homo-4-mer29-145
100
Neutron structure of human transthyretin (TTR) at room temperature to 2.3A resolution (monochromati…homo-4-mer29-145
100
Human transthyretin (TTR) complexed with 4-hydroxy-chalconehomo-4-mer31-147
100IPJ;
(Biarylamine-FT2-WT)1(C10A)3-human transthyretin in the compressed conformationhomo-4-mer29-145
100P2C;
(Biarylamine-FT2-WT)1(C10A)3-human transthyretin in the frayed conformationhomo-4-mer29-145
100P2C;
Unliganded human transthyretin in the canonical conformationhomo-4-mer29-145
100
Human transthyretin covalently modified with A2-derived stilbene in the compressed conformationhomo-4-mer29-145
1001WZ;
Unliganded human transthyretin in the compressed conformationhomo-4-mer29-145
100
Unliganded human transthyretin in the frayed conformationhomo-4-mer29-145
100
Human transthyretin covalently modified with A2-derived stilbene in the canonical conformationhomo-4-mer29-145
1001WZ;
X-ray crystal structure of V30M-TTR in complex with pinostilbenehomo-4-mer30-145
99.148KZ;NA;
Crystal structure of human transthyretin in complex with 3-O-methyltolcapone analogue 2homo-4-mer30-145
100TQ0;
CRYSTAL STRUCTURE of HUMAN TRANSTHYRETIN IN COMPLEX WITH LUTEOLIN AT 1.1 A RESOLUTIONhomo-4-mer30-145
100LU2;GOL;NA;
Transthyretin in complex with the fluorescent folding sensor (E)-7-hydroxy-3-(4-hydroxy-3,5-dimethy…homo-4-mer30-145
1001W3;
Structure of human transthyretin in complex with Tolcaponehomo-4-mer30-145
100TCW;
Crystal structure of Human Transthyretin at 1.15 Angstrom resolutionhomo-4-mer30-145
100NA;
V30G Transthyretin structure in complex with Tolcalponehomo-4-mer30-145
99.14TCW;
Transthyretin in complex with (E)-3-(dimethylamino)-5-(4-hydroxy-3,5-dimethylstyryl)benzoic acidhomo-4-mer30-145
1001WZ;
The Structure of V122I Mutant Transthyretin in Complex with AG10homo-4-mer30-145
99.1416V;
Crystal structure of human transthyretin in complex with 3-O-methyltolcapone analogue 1homo-4-mer30-145
100U1F;
The Structure of V122I Mutant Transthyretin in Complex with Tafamidishomo-4-mer30-145
99.133MI;
Crystal structure of human wild type transthyretin in complex with (3,4-dihydroxy-5-nitrophenyl)-(3…homo-4-mer30-145
100AQI;
Structure of human transthyretin mutant A109Vhomo-4-mer30-145
99.14
Crystal Structure of human transthyretin (TTR) processed with the CrystalDirect automated mounting …homo-4-mer30-145
100
Crystal structure of human V30M transthyretin in complex with PITB (Pharmacokinetically Improved TT…homo-4-mer30-145
99.14ZP2;
Crystal Structure of Human Transthyretin in Complex with Perfluorooctanoic acid (PFOA)homo-4-mer30-145
1008PF;NA;
Crystal structure of transthyretin in complex with 3-deoxytolcapone, a tolcapone analoguehomo-4-mer30-145
100LVB;
Kinetic stabilization of transthyretin through covalent modification of K15 by (E)-N-(4-(4-hydroxy-…homo-4-mer30-145
10018J;
X-ray structure of TTR mutant - T119M at 1.22A resolutionhomo-4-mer30-145
99.14
X-ray structure of perdeuterated TTR mutant - T119M at 1.22Ahomo-4-mer30-145
99.14
Kinetic Stabilization of transthyretin through covalent modification of K15 by 4-bromo-3-(5-(3,5-di…homo-4-mer30-145
1000UC;
X-ray structure of TTR mutant - S52P at 1.23A resolutionhomo-4-mer30-145
99.14GOL;
Crystal structure of human V122I transthyretin in complex with PITB (Pharmacokinetically Improved T…homo-4-mer30-145
99.14ZP2;
Transthyretin binding heterogeneity and anti-amyloidogenic activity of natural polyphenols and thei…homo-4-mer30-145
100SO4;R3X;DMS;
Crystal structure of human transthyretin in complex with luteolin-Cl at 1.25 A resolutionhomo-4-mer30-145
1007LU;NA;GOL;
Human transthyretin (TTR) complexed with 3-(9H-fluoren-9-ylideneaminooxy)propanoic acid in a dual b…homo-4-mer30-145
1006BD;GOL;
Transthyretin in complex with (3,4-dihydroxy-5-nitrophenyl)(2-fluorophenyl)methanonehomo-4-mer30-145
1003M1;
High resolution crystal structure of human transthyretin bound to ligand and conjugates of 3-(5-(3,…homo-4-mer30-145
99.144AJ;
Crystal structure of human transthyretin in complex with 3-O-methyltolcapone, a tolcapone analoguehomo-4-mer30-145
100LVE;
Crystal Structure of Human Transthyretin in Complex with Perfluoroktansulfonsyra (PFOS)homo-4-mer30-145
100P8S;NA;
Wild Type Human Transthyretin pH 7.5homo-4-mer30-145
100.0CA;
X-ray structure of perdeuterated TTR mutant - S52P at 1.28A resolutionhomo-4-mer30-145
99.14GOL;
X-ray structure of wild-type TTR at 1.30A resolutionhomo-4-mer30-145
100
Crystal structure of transthyretin in complex with CHF5075, a flurbiprofen analoguehomo-4-mer30-145
100JTN;
CRYSTAL STRUCTURE OF HUMAN TRANSTHYRETIN AT 1.5A RESOLUTIONhomo-4-mer30-145
100
Crystal structure of transthyretin in complex with CHF5075, a flurbiprofen analoguehomo-4-mer30-145
100JTE;
Structure of human transthyretin mutant A108Vhomo-4-mer30-145
99.14
Human transthyretin (TTR) complexed with (2,7-Dichloro-fluoren-9-ylideneaminooxy)-acetic acid.homo-4-mer30-145
1005JW;
Transthyretin in complex with a covalent small molecule kinetic stabilizerhomo-4-mer30-145
100A93;
Transthyretin in complex with (E)-N-(3-(4-hydroxy-3,5-dimethylstyryl)phenyl)acrylamidehomo-4-mer30-145
10016L;
High resolution crystal structure of human transthyretin bound to ligand and conjugates of 4-(5-(3,…homo-4-mer30-145
99.142WN;4B8;
Transthyretin binding heterogeneity and anti-amyloidogenic activity of natural polyphenols and thei…homo-4-mer30-145
100SO4;R4G;
Crystal structure of human transthyretin in complex with luteolin-MeO at 1.35 A resolutionhomo-4-mer30-145
1006B5;NA;
Complex of Transthyretin with resveratrol exhibits multiple binding modeshomo-4-mer30-145
100.0STL;GOL;NA;
Crystal structure of human transthyretin mutant T119M at pH 5.5homo-4-mer30-145
99.14
Crystal structure of the F87M/L110M mutant of human transthyretin at pH 4.6homo-4-mer30-145
98.2815×ZN; 12×ACT;GOL;
Transthyretin binding heterogeneity and anti-amyloidogenic activity of natural polyphenols and thei…homo-4-mer30-145
100SO4;R3S;DMS;
Crystal structure of Transthyretin-quercetin complexhomo-4-mer30-145
100DMS;QUE;
X-ray crystal structure of V30M-TTR in complex with oxyresveratrolhomo-4-mer30-145
99.14EZE;NA;
Human transthyretin (TTR) complexed with Quercetin 3-O-beta-D-galactosidehomo-4-mer30-145
100EDO;J6O;IMD;
Crystal Structure of Human Transthyretin in Complex with Tetrabromobisphenol A (TBBPA)homo-4-mer30-145
100XDI;NA;
Structure of transthyretin in complex with the kinetic stabilizer 201homo-4-mer30-145
100IIH;
Crystal Structure Of Human Transthyretin in complex with 2,4,5-trichlorophenoxyacetic acid (2,4,5-T)homo-4-mer30-145
100F52;
Crystal structure of V30M mutated transthyretin in complex with alpha-mangostinhomo-4-mer30-145
99.14MKS;CL;CA;
X-ray crystal structure of V30M-TTR in complex with isorhapontigeninhomo-4-mer30-145
99.14P5O;NA;
Kinetic Stabilization of transthyretin through covalent modification of K15 by 3-(5-(3,5-dichloro-4…homo-4-mer30-145
1000UA;
Human transthyretin (TTR) complexed with (2,7-Dibromo-fluoren-9-ylideneaminooxy)-acetic acidhomo-4-mer30-145
100L32;DMS;
X-ray structure of perdeuterated wild-type TTR at 1.42A resolutionhomo-4-mer30-145
100
Crystal structure of DACM wild type Transthyretinhomo-4-mer30-145
100
Crystal Structure of Human Transthyretin Ser85Pro Mutanthomo-4-mer30-145
99.14NA;CL;
Crystal structure of human transthyretin double mutant K35T/T119Mhomo-4-mer30-145
98.28
Wild-type Transthyretin in complex with 3-[(1E)-2-(4-Hydroxyphenyl)ethenyl]benzoic Acidhomo-4-mer30-145
100XOS;
Structure of human transthyretin mutant A108Ihomo-4-mer30-145
99.14
Crystal Structure of Human Transthyretin in Complex with 2,2',4,4'-tetrahydroxybenzophenone (BP2)homo-4-mer30-145
10027M;NA;GOL;
Wild-type Transthyretin in complex with 3-[(1E)-2-(2-Chloro-4-boronic acid)ethenyl]benzoic Acidhomo-4-mer30-145
100XLB;
Human transthyretin (TTR) complexed with 4-(3-(2-flourophenoxy)propyl)-3,5-dimethyl-1H-pyrazolehomo-4-mer30-145
1003M3;
Crystal Structure of Human Transthyretin in Complex with Clonixinhomo-4-mer30-145
1006J3;NA;
Kinetic stabilization of transthyretin through covalent modification of K15 by (E)-N-(4-(4-hydroxy-…homo-4-mer30-145
10018A;
Crystal structure of transthyretin in complex with CHF4795, a flurbiprofen analoguehomo-4-mer30-145
100JTK;
Crystal structure of wild-type transthyretin in complex with rafoxanidehomo-4-mer30-145
100OX9;NA;
Crystal structure of transthyretin mutant A25T in complex with CHF5074, a flurbiprofen analoguehomo-4-mer30-145
99.14H50;PO4;
Crystal Structure of Human Transthyretin in Complex with 2,6-Dinitro-p-cresol (DNPC)homo-4-mer30-145
1006J1;NA;
Crystal structure of V30M mutated transthyretin in complex with gamma-mangostinhomo-4-mer30-145
99.14MKT;CL;
Wild-type Transthyretin in complex with 1,1'-(1E)-(1,2-Ethenediyl)bis[2-chloro-4-boronic acid]benze…homo-4-mer30-145
100IWW;
Human transthyretin (TTR) complexed with (Z)-((3,4-Dichloro-phenyl)-methyleneaminooxy)-acetic acidhomo-4-mer30-145
100L57;
Covalent modification of transthyretin K15 by yielding the fluorescent conjugate (E)-3-(dimethylami…homo-4-mer30-145
1001W4;
Transthyretin binding heterogeneity and anti-amyloidogenic activity of natural polyphenols and thei…homo-4-mer30-145
100D75;
Human transthyretin (TTR) complexed with 5-(2-ethoxyphenyl)-3-(pyridin-4-yl)-1,2,4-oxadiazolehomo-4-mer30-145
1003M4;
Wild-type Transthyretin in complex with 5-[(1E)-2-(4-Boronic acid)ethenyl]-1,3-benzenediolhomo-4-mer30-145
100S4B;
Human transthyretin (TTR) in complex with 3,5-Dibromo-4-hydroxystilbenehomo-4-mer30-145
100LJ2;
Complex of Human Transthyretin with 3',5'-Dichlorophenylanthranilic Acidhomo-4-mer30-145
100FQ7;
Transthyretin binding heterogeneity and anti-amyloidogenic activity of natural polyphenols and thei…homo-4-mer30-145
100G7G;
Human Transthyretin Ser52Pro Mutanthomo-4-mer30-145
99.14CA;
Crystal structure of TTR/resveratrol/T4 complexhomo-4-mer30-145
99.14T44;STL;
Wild type human transthyretin (TTR) complexed with GC-1 (TTRwt:GC-1)homo-4-mer30-145
100B72;GOL;
Crystal structure of V30M mutant human transthyretin complexed with nordihydroguaiaretic acidhomo-4-mer30-145
99.1430Z;
Wild-type Transthyretin in complex with 3-[(1E)-2-(2-Chloro-4-hydroxyphenyl)ethenyl]benzoic Acidhomo-4-mer30-145
100XLO;
V30M Transthyretin structure in complex with Tolcalponehomo-4-mer30-145
99.14TCW;
Crystal structure of human transthyretin double mutant R34G/T119M at pH 5.5homo-4-mer30-145
98.28
Human transthyretin (TTR) complexed with (R)-3-(9H-fluoren-9-ylideneaminooxy)-2-methyl-N-(methylsul…homo-4-mer30-145
10048R;GOL;
Crystal Structure of Human Transthyretin in Complex with 3,5,6-Trichloro-2-pyridinyloxyacetic acid …homo-4-mer30-145
100SBK;NA;
Crystal structure of transthyretin variant V20Shomo-4-mer30-145
99.14
Crystal structure of V30M mutant human transthyretin complexed with dihydroguaiaretic acidhomo-4-mer30-145
99.14PWK;
Crystal Structure of the Wild Type TTR Binding Naringenin (TTRwt:NAR)homo-4-mer30-145
10020×EDO;NAR;CA;
Crystal Structure of Human Transthyretin Lys15Trp Mutanthomo-4-mer29-144
99.14
Crystal structure of the transthyretin mutant A108Y/L110E solved in space group p21212homo-4-mer30-145
98.28
Crystal Structure Of Human Transthyretin in complex with 3,5,6-trichloro-2-pyridinol (TC2P)homo-4-mer30-145
100F4Z;NA;
Transthyretin conjugated with a tafamidis derivativehomo-4-mer30-145
100OIT;
A25T Transthyretin structure in complex with Tolcalponehomo-4-mer30-145
99.14TCW;
Structure of transthyretin pathogenic mutation A120Shomo-4-mer30-145
99.14
Structure of human transthyretin mutant E89Khomo-4-mer30-145
99.14
Crystal structure of the apo form of human wild-type transthyretinhomo-4-mer30-145
100
Crystal Structure of Human Transthyretin in Complex with 4,4'-Dihydroxydiphenyl sulfone (Bisphenol …homo-4-mer30-145
1006JD;NA;
Probing the dissociation pathway of a kinetically labile transthyretin mutant (A25T)homo-4-mer30-145
99.14
Crystal structure of V30L mutated human transthyretinhomo-4-mer30-145
99.13MG;
Crystal structure of V30G mutated human transthyretinhomo-4-mer30-145
99.11MG;
Crystal structure of human transthyretin variant A25T - #1homo-4-mer30-145
99.14PGE;
Crystal structure of transthyretin in complex with CHF5074 at neutral pHhomo-4-mer30-145
100H50;
Crystal structure of transthyretin in complex with diflunisal at acidic pHhomo-4-mer30-145
99.141FL;
Human TTR altered by a rhenium tris-carbonyl Pyta-C8 derivativehomo-4-mer30-145
100DMS;EDO;ACT;RE;IMD;
transthyretin with tethered inhibitor on one monomer.homo-4-mer30-145
100P2C;
Crystal structure of TTR variant I84S in complex with CHF5074 at acidic pHhomo-4-mer30-145
99.14H50;
Crystallographic study of novel transthyretin ligands exhibiting negative-cooperativity between two…homo-4-mer30-145
100
The crystal structure of 2,4-dinitrophenol in complex with human transthyretinhomo-4-mer30-145
100SO4;DNF;
Crystal structure of transthyretin in complex with iododiflunisalhomo-4-mer30-145
100FHI;
Structure of human transthyretin complex with analgesic inhibitorhomo-4-mer30-145
99.14FQ7;NA;
Crystal structure of Human Transthyretin (E54G)homo-4-mer30-145
99.14GOL;SO4;
V30M mutant human transthyretin (TTR) complexed with GC-24 (V30M:GC-24)homo-4-mer30-145
99.14GOL;G24;
Crystal structure of the transthyretin mutant TTR C10A/Y114Chomo-4-mer30-145
98.2812×BME;
Wild-type Transthyretin in complex with 3-[(1E)-2-(4-Boronic acid)ethenyl]benzoic Acidhomo-4-mer30-145
100XBS;
Crystal structure of DACM F87M/L110M Transthyretin mutanthomo-4-mer30-145
98.28CL;ACT;
Crystal structure of human transthyretin variant V30M in complex with luteolinhomo-4-mer30-145
99.14LU2;NA;
Y114C Transthyretin structure in complex with Tolcalponehomo-4-mer30-145
99.14TCW;
Human transthyretin (TTR) complexed with (E)-3-(((4-hydroxybenzylidene)amino)oxy)propanoic acidhomo-4-mer29-144
100NEK;
Crystal Structure of the Wild Type TTR Binding Chrysin (TTRwt:CHR)homo-4-mer30-145
10057D;
V30M mutant human transthyretin (TTR) complexed with GC-1 (V30M:GC-1)homo-4-mer30-145
99.14B72;GOL;
Crystal structure of human transthyretin variant C10A/M13Vhomo-4-mer30-145
98.28CA;
Crystal Structure of Human Transthyretin in Complex with Gemfibrozilhomo-4-mer30-145
1004TX;NA;
Transthyretin in complex with (E)-5,5'-(ethene-1,2-diyl)bis(1,1-dihydroxy-3-oxo-1,3-dihydrobenzo[c]…homo-4-mer30-145
100S2B;
Crystal Structure of Human Transthyretin Val30Met Mutanthomo-4-mer30-145
99.13
Crystal structure of the F87M/L110M mutant of human transthyretin at pH 6.5homo-4-mer30-145
98.2812×ZN;GOL;ACT;
Crystal structure of the F87M/L110M mutant of human transthyretin at pH 5.5homo-4-mer30-145
98.2612×ZN; 10×ACT;GOL;
Crystal structure of the F87M/L110M mutant of human transthyretin at pH 4.6 soakedhomo-4-mer30-145
98.2812×ZN;ACT;GOL;
Crystal structure of V30M mutant human transthyretin complexed with caffeic acid ethyl esterhomo-4-mer30-145
99.140XR;CA;
Crystal structure of V30M mutant human transthyretin complexed with caffeic acid 1,1-dimethylallyl …homo-4-mer30-145
99.14PWH;CA;
Crystal structure of transthyretin variant L58H at acidic pHhomo-4-mer30-145
99.14
Structure of human transthyretin complexed with bromophenols: a new mode of bindinghomo-4-mer30-145
100TBP;
Crystal structure of transthyretin mutant I84S at PH 7.5homo-4-mer30-145
99.14
Wild-type Transthyretin in complex with 2-Boronic Acid-1-[(1E)-2-(3-boronic acid)ethenyl]-4-chlorob…homo-4-mer30-145
1007UV;
Structure of human transthyretin complexed with bromophenols: a new mode of bindinghomo-4-mer30-145
100GOL;PBR;
CRYSTAL STRUCTURE OF TRANSTHYRETIN IN COMPLEX WITH LIGAND C-18homo-4-mer30-145
100HKA;
CRYSTAL STRUCTURE OF TRANSTHYRETIN IN COMPLEX WITH LIGAND C-17homo-4-mer30-145
100FT0;
Human TTR crystals soaked in manganese chloride.homo-4-mer30-145
100MN;
Crystal structure of human transthyretin variant A25T - #2homo-4-mer30-145
99.14PGE;
Crystal structure of V30I mutated human transthyretinhomo-4-mer30-145
99.11MG;
Human TTR altered by a rhenium tris-carbonyl Pyta-C12 derivativehomo-4-mer30-145
100EDO;PEG;RE;ACT;DMS;IMD;
Crystal structure of transthyretin variant L55P at neutral pHhomo-4-mer30-145
99.14
Crystal structure of human transthyretin at pH 4.6homo-4-mer30-145
100
Crystal structure of human wild type transthyretin in complex with PITB (Pharmacokinetically Improv…homo-4-mer30-145
100ZP2;
Human transthyretin (TTR) complexed with (S)-3-(9H-fluoren-9-ylideneaminooxy)-2-methylpropanoic aci…homo-4-mer29-144
1006BD;
X-ray structure of human transthyretin (TTR) at room temperature to 1.9A resolutionhomo-4-mer30-145
100
Crystal structure of transthyretin variant L55P at acidic pHhomo-4-mer30-145
99.14
Crystal structure of human transthyretin in complex with 1-amino-5-naphthalene sulfonatehomo-4-mer30-145
1005NS;
Crystal structure of V30M mutated transthyretin in complex with 3-isomangostinhomo-4-mer30-145
99.14MKU;
Crystal Structure of the Wild Type TTR Binding Luteolin (TTRwt:LUT)homo-4-mer30-145
100LU2;
Crystal structure of the F87M/L110M mutant of human transthyretin at pH 7.5homo-4-mer30-145
98.2812×ZN;ACT;GOL;
Crystal structure of wild-type human transthyretin in complex with sulindachomo-4-mer30-145
100SUZ;
Crystal structure of human transthyretin with bound chloridehomo-4-mer30-145
10012×CL;
Crystal Structure of the Wild Type TTR Binding Apigenin (TTRwt:API)homo-4-mer30-145
100AGI;GOL;
Wild-type Transthyretin in complex with 5-[(1E)-2-(2-Chloro-4-boronic acid)ethenyl]-1,3-benzenediolhomo-4-mer30-145
1007VG;
Structure of human transthyretin complexed with bromophenols: a new mode of bindinghomo-4-mer30-145
100
Crystal structure of wild-type human transthyretinhomo-4-mer30-145
100
Crystal structure of human transthyretin variant A25T in complex with thyroxine (T4)homo-4-mer30-145
99.14T44;
Crystal structure of human transthyretin - wild typehomo-4-mer30-145
100
Crystal structure of wild-type human transthyretin in complex with sulindachomo-4-mer30-145
100SUZ;
Crystal structure of transthyretin mutant 87-110-117homo-4-mer30-145
97.41
V30M mutant human transthyretin (TTR) complexed with genistein (V30M:GEN) pH 7.5homo-4-mer30-145
99.14GEN;
Crystal Structure of Human Transthyretin (E54K)homo-4-mer30-145
99.1410×GOL;SO4;
Structure of transthyretin L55P in complex with Znhomo-4-mer30-145
99.14ZN;CAC;
Crystal structure of wild-type human transthyretin in complex with indomethacinhomo-4-mer30-145
100IMN;
CRYSTAL STRUCTURE OF THE TRANSTHYRETIN MUTANT TTR Y114C-DATA COLLECTED AT CRYO TEMPERATUREhomo-4-mer30-145
99.1412×BME;
Crystal structure of human transthyretin in complex with lumiracoxibhomo-4-mer30-145
100LUR;
Crystal structure of Human Transthyretin (wild-type)homo-4-mer30-145
100SO4;GOL;
Wild type human transthyretin (TTR) complexed with GC-24 (TTRwt:GC-24)homo-4-mer30-145
100G24;
Transthyretin natural mutant A25Thomo-4-mer30-145
99.14
Crystal Structure of the Wild Type TTR Binding Kaempferol (TTRwt:KAE)homo-4-mer30-145
100KMP;
Structure of transthyretin synthetic mutation A120Lhomo-4-mer29-144
99.14
Crystal structure of human wild-type transthyretin in complex with diclofenachomo-4-mer30-145
100DIF;
Crystal structure of the transthyretin mutant A108Y/L110E solved in space group C2homo-4-mer30-145
98.28
Crystal structure of human transthyretin in complex with indomethacinhomo-4-mer30-145
100IMN;
Crystal structure of wild-type human transthyretin in complex with lumiracoxibhomo-4-mer30-145
100LUR;
Crystal structure of wild-type human transthyretin in complex with sulindachomo-4-mer30-145
100SUZ;
Crystal structure of transthyretin mutant I84A at neutral pHhomo-4-mer30-145
99.14
Wild-type Transthyretin in complex with 5-[(1E)-2-(2-Chloro-4-hydroxyphenyl)ethenyl]-1,3-benzenediolhomo-4-mer30-145
100S2L;
Crystal structure of the highly amyloidogenic transthyretin mutant TTR G53S/E54D/L55S- heated prote…homo-4-mer30-145
97.39
CRYSTAL STRUCTURE OF THE HIGHLY AMYLOIDOGENIC TRANSTHYRETIN MUTANT TTR G53S/E54D/L55Shomo-4-mer30-145
97.39
Crystal structure of transthyretin variant V30M at acidic pHhomo-4-mer30-145
99.14
Crystal structure of transthyretin variant Y114Hhomo-4-mer30-145
99.14
Crystal structure of transthyretin variant Y114H at acidic pHhomo-4-mer30-145
99.14
Crystal structure of transthyretin variant T60A at acidic pHhomo-4-mer30-145
99.14ACT;
Human TTR altered conformation from soaking in CuCl2.homo-4-mer30-145
100CU;PEG;ACT;EDO;
Human TTR altered conformation from soaking in iron chloride.homo-4-mer30-145
100ACT;FFE; 10×FE;
LEU 55 PRO TRANSTHYRETIN CRYSTAL STRUCTUREhomo-4-mer30-145
99.14
MONOCLINIC FORM OF HUMAN TRANSTHYRETIN COMPLEXED WITH THYROXINE (T4)homo-4-mer30-145
100T44;
Neutron structure of human transthyretin (TTR) S52P mutant at room temperature to 1.8A resolution (…homo-4-mer30-145
99.14
Neutron structure of human transthyretin (TTR) T119M mutant at room temperature to 1.85A resolutionhomo-4-mer30-145
99.14
Neutron and X-ray joint structure of WT-TTR in complex with piceatannolhomo-4-mer30-145
100PIT;
Neutron structure of human transthyretin (TTR) S52P mutant in complex with tafamidis at room temper…homo-4-mer30-145
99.143MI;
Crystal structure of human transthyretin in complex with 4-chloro-9,10-dioxo-9,10-dihydroanthracene…homo-4-mer30-144
100CA;HG6;
Human Transthyretin (TTR) complexed with 2-((3,5-dichloro-4-hydroxyphenyl)amino)benzoic acidhomo-4-mer30-144
100CJZ;
Crystal structure of V30M mutated transthyretin in complex with 4-chloro-9-oxo-9H-xanthene-2-carbox…homo-4-mer30-144
99.13CA;HH9;
Crystal structure of human transthyretin in complex with 4-chloro-9-oxo-9H-xanthene-2-carboxylic ac…homo-4-mer30-144
100CA;HH9;
Crystal structure of E61K mutated transthyretinhomo-4-mer30-144
99.13CA;
Human transthyretin (TTR) complexed with 2-(3,5-Dimethyl-4-hydroxyphenyl)benzoxazolehomo-4-mer31-145
100MR4;
Transthyretin in complex with 5-(4-nitrophenylazo)-3-iodosalicylic acidhomo-4-mer30-144
100BQB;
Structure of wild-type TTR in complex with tafamidishomo-4-mer31-145
1003MI;
Crystal structure of V30M mutated transthyretin in complex with purpurinhomo-4-mer30-144
99.139TF;
X-ray crystal structure of V30M-TTR in complex with piceatannolhomo-4-mer30-144
99.13PIT;NA;
Transthyretin in complex with (E)-2,6-dibromo-4-(2,6-dimethoxystyryl)anilinehomo-4-mer31-145
100IW6;
Human transthyretin (TTR) complexed with N-(3,5-Dibromo-4-hydroxyphenyl)-2,5-dichlorobenzamidehomo-4-mer31-145
100DZ2;
Human transthyretin (TTR) complexed with N-(3,5-Dibromo-4-hydroxyphenyl)-3,5-dimethyl-4-hydroxybenz…homo-4-mer31-145
100DZ3;
Crystal structure of transthyretin in complex with apigeninhomo-4-mer30-144
100AGI;
Crystal Structure of Human Transthyretin Glu92Pro Mutanthomo-4-mer30-144
99.13PO4;GOL;NA;
X-ray crystal structure of V30M-TTR in complex with pterostilbenehomo-4-mer30-144
99.133RL;NA;
Human transthyretin (TTR) complexed with N-(3,5-Dibromo-4-hydroxyphenyl)-2,6-dimethylbenzamidehomo-4-mer31-145
100DZ1;
Transthyretin in complex with 4-(1,3-Benzothiazol-2-yl)-2-methylanilinehomo-4-mer30-144
100BM8;
Crystal structure of human transthyretin variant A97S at pH 5.4homo-4-mer30-144
99.1GOL;
Crystal structure of Transthyretin complexed with pterostilbenehomo-4-mer30-144
100SO4;DMS;3RL;
Transthyretin in complex with (E)-4-(4-aminostyryl)-2,6-dibromophenolhomo-4-mer31-145
100IW3;
Transthyretin in complex with 2,6-dibromo-4-(2,6-dichlorophenethyl)phenolhomo-4-mer31-145
100IW2;
Transthyretin in complex with (E)-4-(3-aminostyryl)-2,6-dibromoanilinehomo-4-mer31-145
100IW4;
Human transthyretin (TTR) in Apo-formhomo-4-mer31-145
100
Human Transthyretin (TTR) complexed with a palindromic bivalent amyloid inhibitor (7 carbon linker).homo-4-mer30-144
100JZE;
Crystal structure of transthyretin in complex with L6homo-4-mer30-144
100L6Y;
Crystal structure of V30M mutant human transthyretinhomo-4-mer30-144
99.13
Human transthyretin (TTR) in complex with N-(3,5-Dibromo-4-hydroxyphenyl)benzamidehomo-4-mer31-145
100LJ5;
Crystal Structure of Human Transthyretin Ser85Pro/Glu92Pro Mutanthomo-4-mer30-144
98.26NA;GOL;PEG;
Human transthyretin (TTR) complexed with 2-(3,5-Dimethylphenyl)benzoxazolehomo-4-mer31-145
100MR6;
Crystal structure of Cys10 sulfonated transthyretinhomo-4-mer30-144
100SO4;
Transthyretin complexed with (E)-4-(2-(naphthalen-1-yl)vinyl)benzene-1,2-diolhomo-4-mer31-145
1009RJ;GOL;NA;
Transthyretin complexed with (E)-4-(2-(naphthalen-2-yl)vinyl)benzene-1,2-diolhomo-4-mer31-145
1009PS;
X-ray crystal structure of V30M-TTR in complex with resveratrolhomo-4-mer30-144
99.13STL;NA;
Structure of Human Transthyretin Val30Met Mutant in Complex with Tafamidishomo-4-mer30-144
99.133MI;
Human transthyretin (TTR) complexed with (E)-3-(((3,5-dibromo-2-hydroxybenzylidene)amino)oxy)propan…homo-4-mer30-144
100ND5;GOL;PGO;
Kinetic Stabilization of transthyretin through covalent modification of K15 by 3-(5-(3,5-dichloroph…homo-4-mer31-145
1000U7;
Human transthyretin (TTR) complexed with bivalant amyloid inhibitor (4 carbon linker)homo-4-mer30-144
10044C;
Transthyretin in complex with (E)-4-(4-aminostyryl)-2,6-dibromoanilinehomo-4-mer31-145
100IW5;
Crystal structure of V30M mutated transthyretin with bromide in complex with alpha-mangostinhomo-4-mer30-144
99.13MKS; 12×BR;
Crystal structure of V30M mutant human transthyretin complexed with rosmarinic acidhomo-4-mer30-144
99.13ROA;
Structure of Human Transthyretin Asp38Ala Mutant in Complex with Diflunisalhomo-4-mer30-144
99.131FL;
Structure of Human Transthyretin Asp38Ala Mutanthomo-4-mer30-144
99.13ACT;
Structure of Human Transthyretin Val30Met/Thr119Met Mutanthomo-4-mer30-144
98.26PEG;
Human transthyretin (TTR) complexed with 2-(3,5-Dibromo-4-hydroxyphenyl)benzoxazolehomo-4-mer31-145
100MR5;
Crystal structure of V30M mutated transthyretin with bromide in complex with gamma-mangostinhomo-4-mer30-144
99.13MKT; 16×BR;
Crystal structure of V30M mutated transthyretin in complex with 4'-caroboxybenzo-18-Crown-6homo-4-mer30-144
99.13AJU;
Crystal structure of V30M-TTR in complex with compound 20homo-4-mer30-144
99.13WH0;
Human transthyretin (TTR) in complex with 3,5-Dimethyl-4-hydroxystilbenehomo-4-mer31-145
100LJ1;
Human transthyretin (TTR) in complex with 3,5-Dibromo-4-hydroxybiphenylhomo-4-mer31-145
100LJ3;
Crystal structure of human transthyretin variant A97S at pH 7.6homo-4-mer30-144
99.1
Human transthyretin (TTR) complexed with diflunisal analogues- TTR.3',5'-difluorobiphenyl-4-carboxy…homo-4-mer30-144
100.0FBC;
Crystal structure of human transthyretin in complex with Benzbromaronehomo-4-mer30-144
100R75;
Crystal structure of WT-TTR in complex with bithionolhomo-4-mer30-144
100B1T;CA;
Crystal structure of transthyretin in complex with 3,5-diiodosalicylic acidhomo-4-mer30-144
100DIU;
Crystal Structure of Human Transthyretin Thr119Tyr Mutanthomo-4-mer30-144
99.13GOL;
Human Transthyretin expressed in Vibrio natriegenshomo-4-mer30-144
100
The X-ray crystallographic structure of the amyloidogenic variant TTR Tyr78Phehomo-4-mer30-144
99.13
Crystal structure of H88A mutated human transthyretinhomo-4-mer31-145
99.12MPD;MG;
Crystal structure of Transthyretin mutant I84S at acidic pHhomo-4-mer30-144
99.13
Crystal structure of V30M-TTR in complex with naringenin derivative-14homo-4-mer30-144
99.1390Q;CA;
Structure of Human Transthyretin Asp38Ala/Thr119Met Mutanthomo-4-mer30-144
98.26GOL;SO4;ACT;
Structure of Human Transthyretin Leu55Pro Mutant in Complex with Tafamidishomo-4-mer30-144
99.133MI;
Crystal Structure of Human Transthyretin Thr119Met Mutanthomo-4-mer30-144
99.13
Crystal structure of human transthyretinhomo-4-mer30-144
100CA;
Human transthyretin (TTR) complexed with (Z)-5-(3,5-dibromo-4-hydroxybenzylidene)-imino-1-methylimi…homo-4-mer31-145
1003M2;
Structure of Human Transthyretin Asp38Ala Mutant in Complex with Tafamidishomo-4-mer30-144
99.133MI;
Crystal structure of V30M mutant human transthyretin complexed with ferulic acid phenethyl esterhomo-4-mer30-144
99.13PWF;
Human transthyretin (TTR) complexed with diflunisal analogues- TTR. 2',6'-Difluorobiphenyl-4-carbox…homo-4-mer30-144
10026C;
Crystal structure of V30M mutated transthyretin in complex with 18-Crown-6homo-4-mer30-144
99.13O4B;
Human transthyretin (TTR) complexed with bivalant amyloid inhibitor (6 carbon linker)homo-4-mer30-144
1006CA;
Crystal structure of V30M-TTR in complex with compound 7homo-4-mer30-144
99.13WGJ;
Crystal structure of human transthyretinhomo-4-mer30-144
100MG;
Crystal Structure of Transthyretin in Complex With Ligand C-6homo-4-mer30-144
10042M;
Crystal Structure of Human Transthyretin Thr119Trp Mutanthomo-4-mer30-144
99.13
Transthyretin in complex with (E)-2,6-dibromo-4-(2,6-dichlorostyryl)phenolhomo-4-mer31-145
100IW1;
CRYSTAL STRUCTURE OF TRANSTHYRETIN IN COMPLEX WITH LIGAND C-1homo-4-mer30-144
1004V2;
Human transthyretin (TTR) complexed with Diflunisal analogues- TTR.2',4'-DICHLORO-4-HYDROXY-1,1'-BI…homo-4-mer30-144
1003CA;
Crystal structure of V30M-TTR in complex with dasatinibhomo-4-mer30-144
99.131N1;
Crystal structure of human transthyretin variant A97S complexed with Tolcaponehomo-4-mer30-144
99.11TCW;
Crystal structure of human Transthyretin (TTR) at pH 4.0homo-4-mer30-144
100
Crystal Structure of Human Transthyretin Ala108Trp Mutanthomo-4-mer30-144
99.13CL;
Structure of Wild Type Human Transthyretin in Complex with Tafamidishomo-4-mer30-144
1003MI;
TRANSTHYRETIN STABILITY AS A KEY FACTOR IN AMYLOIDOGENESIShomo-4-mer30-144
99.13
The crystal structure of 2,4-dinitrophenol in complex with the amyloidogenic variant Transthyretin …homo-4-mer30-144
99.13DNF;
Human transthyretin (TTR) complexed with 3-(9H-fluoren-9-ylideneaminooxy)propanoic acid (inhibitor …homo-4-mer30-144
1007BD;
Crystal structure of V30M mutant human transthyretin complexed with glabridinhomo-4-mer30-144
99.13GBJ;
Structure of Human Transthyretin Val30Met Mutant in Complex with Diflunisalhomo-4-mer30-144
99.131FL;ACT;
V30M mutant human transthyretin (TTR) (apoV30M) pH 7.5homo-4-mer30-144
99.13
Crystal Structure of Human Transthyretin Leu55Pro Mutanthomo-4-mer30-144
99.13
Human transthyretin (TTR) complexed with (E)-3-(2-methoxybenzylideneaminooxy)propanoic acid (inhibi…homo-4-mer30-144
1008BD;
Crystal structure of human Transthyretin with bound iodidehomo-4-mer30-144
10012×IOD;
Human transthyretin (TTR) in complex with 1,3-Dibromo-2-hydroxy-5-phenoxybenzenehomo-4-mer31-145
100LJ4;
Crystal structure of transthyretin in complex with iododiflunisal-betaAlaOHhomo-4-mer30-144
100IFB;
CRYSTAL STRUCTURE OF TRANSTHYRETIN IN COMPLEX WITH LIGAND C-3homo-4-mer30-144
100FT2;
The orthorhombic crystal structure of transthyretin in complex with diethylstilbestrolhomo-4-mer30-144
100SO4;DES;GOL;
Crystal structure of A97S transthyretinhomo-4-mer30-144
99.08
Human Transthyretin (TTR) Complexed with Hydroxylated polychlorinated Biphenyl-4,4'-dihydroxy-3,3',…homo-4-mer30-144
100PCQ;
Crystal structure of V30M mutant human transthyretin complexed with caffeic acid phenethyl esterhomo-4-mer30-144
99.13QAP;
Crystal structure of V30M-TTR in complex with compound 4homo-4-mer30-144
99.13WGH;
CRYSTAL STRUCTURE OF TRANSTHYRETIN IN COMPLEX WITH LIGAND C-7homo-4-mer30-144
10043F;
Crystal structure of V30M-TTR in complex with triclabendazolehomo-4-mer30-144
99.13JA9;
Wild type human transthyretin (TTR) complexed with genistein (TTRwt:GEN) pH 7.5homo-4-mer30-144
100GEN;
The monoclinic crystal structure of transthyretin in complex with diethylstilbestrolhomo-4-mer30-144
100ACT;DMS;GOL;DES;
Crystal structure of transthyretin in complex with iododiflunisal-betaAlaOMehomo-4-mer30-144
100IFA;
Human Transthyretin (TTR) Complexed with Hydroxylated polychlorinated Biphenyl-4-hydroxy-2',3,3',4'…homo-4-mer30-144
100NE1;
Human transthyretin (ttr) complexed with diflunisalhomo-4-mer30-144
1001FL;
CRYSTAL STRUCTURE OF TRANSTHYRETIN IN COMPLEX WITH LIGAND C-2homo-4-mer30-144
100FT1;
Crystal structure of human transthyretin in complex with 1-anilino-8-naphthalene sulfonatehomo-4-mer30-144
1002AN;
Crystal structure of Transthyretin variant A97S in monomeric formhomo-4-mer30-144
97.39MPD;
Crystal structure of V30M-TTR in complex with dichlorophenhomo-4-mer30-144
99.13JAL;CA;
CRYSTAL STRUCTURE OF HUMAN TRANSTHYRETIN IN COMPLEX WITH FLURBIPROFENhomo-4-mer30-144
99.13FLP;
CRYSTAL STRUCTURE OF HUMAN TRANSTHYRETIN IN COMPLEX WITH DIBENZOFURAN-4,6-DICARBOXYLIC ACIDhomo-4-mer30-144
99.13DBF;
CRYSTAL STRUCTURE OF TRANSTHYRETIN IN COMPLEX WITH N-(M-TRIFLUOROMETHYLPHENYL) PHENOXAZINE-4,6-DICA…homo-4-mer30-144
99.13BPD;
CRYSTAL STRUCTURE OF HUMAN TRANSTHYRETIN IN COMPLEX WITH O-TRIFLUOROMETHYLPHENYL ANTHRANILIC ACIDhomo-4-mer30-144
99.13OFL;
Human Transthyretin (TTR) complexed with a palindromic bivalent amyloid inhibitor (11 carbon linker…homo-4-mer30-144
100JZD;
Crystal structure of Transthyretin mutant I84A at low pHhomo-4-mer30-144
99.12
Crystal structure of human transthyretin variant A97S complexed with Diflunisalhomo-4-mer30-144
99.11FL;
Structure of Wild Type Human Transthyretin in Complex with Diflunisalhomo-4-mer30-144
1001FL;CA;
Crystal structure of V30M-TTR in complex with naringenin derivative-18homo-4-mer30-144
99.1391C;
The crystal structure of 2,4-dinitrophenol in complex with the amyloidogenic variant Transthyretin …homo-4-mer30-144
99.13DNF;
CRYSTAL STRUCTURE OF THE TRANSTHYRETIN MUTANT TTR Y114C-DATA COLLECTED AT ROOM TEMPERATUREhomo-4-mer30-144
99.1312×BME;
CRYSTAL STRUCTURE OF HUMAN TRANSTHYRETIN IN COMPLEX WITH RESVERATROLhomo-4-mer30-144
99.13STL;
CRYSTAL STRUCTURE OF HUMAN TRANSTHYRETINhomo-4-mer30-144
99.13
CRYSTAL STRUCTURE OF HUMAN TRANSTHYRETIN IN COMPLEX WITH DICLOFENAChomo-4-mer30-144
99.13DIF;
Crystal structure of human transthyretin complexed with glabridinhomo-4-mer30-144
100GBJ;CA;
CRYSTAL STRUCTURE OF TRANSTHYRETIN VARIANT L58H at neutral pHhomo-4-mer30-144
99.13
An Engineered Transthyretin Monomer that is Non-amyloidogenic - Unless Partially Denaturedhomo-4-mer30-144
98.26
Cryo-EM structure of cardiac amyloid fibril from a variant ATTR I84S amyloidosis patient-3, variant…homo-4-mer30-144
98.92
Crystal structure of I73L mutated human transthyretinhomo-4-mer31-144
99.12MG;
Crystal structure of Transthyretin in complex with a covalent inhibitor trans-styrylpyrazolehomo-4-mer31-144
100XHF;XHB;
Crystal structure of H88S mutated human transthyretinhomo-4-mer31-144
99.12
X-ray crystal structure of human Transthyretin at room temperaturehomo-4-mer32-145
100
Crystal structure of human Transthyretin (TTR) at pH3.5homo-4-mer31-144
100
Crystal structure of P113A mutated human transthyretinhomo-4-mer31-144
99.12SO4;CL;
Crystal structure of H88Y mutated human transthyretinhomo-4-mer31-144
99.12SO4;CL;
TRANSTHYRETIN STABILITY AS A KEY FACTOR IN AMYLOIDOGENESIShomo-4-mer30-143
95.24
Human Transthyretin (TTR) Complexed with Hydroxylated polychlorinated Biphenyl-4-hydroxy-3,3',5,4'-…homo-4-mer30-143
100.0NE2;
V122I Transthyretin structure in complex with Tolcalponehomo-4-mer30-143
99.12TCW;
Crystal structure of H88F mutated human transthyretinhomo-4-mer31-144
99.1SO4;
HUMAN TRANSTHYRETIN (PREALBUMIN) COMPLEX WITH FLUFENAMIC ACID (2-[[3-(TRIFLUOROMETHYL)PHENYL]AMINO]…homo-4-mer30-143
100FLF;
Neutron crystal structure of human Transthyretinhomo-4-mer32-145
100
a covalent dimer of transthyretin that affects the amyloid pathwayhomo-4-mer31-143
100.0
THE X-RAY CRYSTAL STRUCTURE REFINEMENTS OF NORMAL HUMAN TRANSTHYRETIN AND THE AMYLOIDOGENIC VAL 30-…homo-2-mer21-147
96.67T44;
TRANSTHYRETIN COMPLEX WITH RETINOIC ACIDhomo-2-mer21-147
1009CR;
THE X-RAY CRYSTAL STRUCTURE REFINEMENTS OF NORMAL HUMAN TRANSTHYRETIN AND THE AMYLOIDOGENIC VAL 30-…homo-2-mer29-146
99.15T44;
TRANSTHYRETIN-V/122/I CARDIOMYOPATHIC MUTANThomo-2-mer28-145
99.14
Transthyretin natural mutant A19Dhomo-2-mer30-145
99.14CA;
Crystal structure of human transthyretin variant A25T in complex with flufenamic acid.homo-2-mer30-145
99.14FLF;
TRANSTHYRETIN THR119MET PROTEIN STABILISATIONhomo-2-mer30-144
99.13T44;
Crystal structure of human transthyretin in complex with 8-chloro-9-oxo-9H-xanthene-3-carboxylic ac…homo-2-mer30-144
100CA;J5R;
Crystal structure of V30M-TTR in complex with 6-hydroxy BIDhomo-2-mer30-144
99.13PKK;
Crystal structure of V30M mutated transthyretin in complex with 8-chloro-9-oxo-9H-xanthene-3-carbox…homo-2-mer30-144
99.13CA;J5R;
Crystal structure of V30M-TTR in complex with 6-hydroxy BBMhomo-2-mer30-144
99.13PKQ;
Human transthyretin (TTR) complexed with Benzoxazolehomo-2-mer30-144
100205;
Human Transthyretin (TTR) complexed with(E)-3-(2-(trifluoromethyl)benzylideneaminooxy)propanoic aci…homo-2-mer30-144
1001BD;
Crystal structure of V30M-TTR in complex with BBMhomo-2-mer30-144
99.13R75;CA;
Crystal structure of V30M-TTR in complex with BIDhomo-2-mer30-144
99.13PJO;
STRUCTURE OF PREALBUMIN, SECONDARY, TERTIARY AND QUATERNARY INTERACTIONS DETERMINED BY FOURIER REFI…homo-2-mer30-143
99.12
HUMAN TRANSTHYRETIN (PREALBUMIN)homo-2-mer30-143
100
Solution structure of the T119M variant of transthyretin in its monomeric statemonomer21-147
97.64
Solution structure of the F87M/L110M variant of transthyretin in the monomeric statemonomer21-147
98.42

1 SWISS-MODEL model

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
1kgj.1.Ahomo-4-mer0.8625-146
FL8;83.33